Mt2 - metallothionein 2 Gene

Also Known as Mt-2; MT-II

Species: Mus musculus

Gene Type: protein coding
Gene ID: 17750

Summary

Predicted to enable cadmium ion binding activity and zinc ion binding activity. Acts upstream of or within several processes, including cellular zinc ion homeostasis; detoxification of copper ion; and nitric oxide mediated signal transduction. Predicted to be located in cytosol. Predicted to be active in cytoplasm and nucleus. Is expressed in several structures, including alimentary system; liver lobe; lung; sensory organ; and vibrissa. Human ortholog(s) of this gene implicated in carotid stenosis and type 2 diabetes mellitus. Orthologous to several human genes including MT1X (metallothionein 1X). [provided by Alliance of Genome Resources, Apr 2022]

Mt2 Products (1)

mRNA Protein Name
NM_008630.2 NP_032656.1 metallothionein-2

Gene Ontology

  • Biological Process
Biological Process GO Annotation Evidence References Source
acts upstream of or within detoxification of copper ion IMP
IMP: Inferred from mutant phenotype
8640230 MGI
acts upstream of or within intracellular zinc ion homeostasis IMP
IMP: Inferred from mutant phenotype
11792622 MGI
acts upstream of or within nitric oxide mediated signal transduction IMP
IMP: Inferred from mutant phenotype
11792622 MGI
acts upstream of or within response to bacterium IEP
IEP: Inferred from expression pattern
23012479 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

metallothionein-2

  • metallothionein-II

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-A0014 Ramelteon Agonist 99.85% Yes
HY-14803 Tasimelteon Agonist 99.16% Yes

Clinical Phase

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Phase
HY-105285 Piromelatine Agonist 99.70% Phase 3
HY-106136 TIK-301 Agonist / Phase 2

Pre-clinical Phase

Bioactive Molecules (18)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-101254 Luzindole Antagonist 99.62% Unkown
HY-100609 4-P-PDOT Antagonist 99.90% Unkown
HY-114962 S-22153 Antagonist 99.94% Unkown
HY-138626 ACH-000143 Agonist 98.58% Unkown
HY-101358 8-M-PDOT Agonist 99.33% Unkown
HY-17038S Agomelatine-d6 Agonist 99.05% Unkown
HY-101074 UCM 608 Agonist 99.18% Unkown
HY-17038S2 Agomelatine-d3 Agonist 98.0% Unkown
HY-A0014S Ramelteon-d5 Agonist 99.83% Unkown
HY-107628 N-Pentanoyl 2-benzyltryptamine Antagonist 99.0% Unkown
HY-17038S1 Agomelatine-d4 Agonist / Unkown
HY-180198 UCM1400 / Unkown
HY-147542 Melatonin receptor agonist 1 Agonist / Unkown
HY-131947 DH97-7 Antagonist / Unkown
HY-115304 UCM 793 Agonist / Unkown
HY-133112 7-Desmethyl-3-hydroxyagomelatine Agonist / Unkown
HY-100940 6-Chloromelatonin Agonist / Unkown
HY-14803S Tasimelteon-d5 Agonist / Unkown